AIMS: To examine retrospectively the relationship between DPD phenotype/genotype and the intensity of 5FU toxicity. METHODS: One hundred and thirty-one case-reports (81 women, 50 men) with 5FU-related toxicity were analyzed. RESULTS: The lower the DPD activity (10-504 pmol min(-1) mg(-1)), the higher the toxicity grade was scored (P < 0.01). Toxicity-related deaths occurred in nine patients (eight women) who significantly expressed lower DPD activity than other patients. Two of the deceased patients had normal DPD activity. The IVS14+1G>A mutation, analyzed in 93 patients, was detected in two patients (nonlethal toxicity). CONCLUSIONS: The IVS14+1G>A mutation may not help prevent toxicity and patients with normal DPD activity may develop life-threatening 5FU toxicity.
AIMS: To examine retrospectively the relationship between DPD phenotype/genotype and the intensity of 5FUtoxicity. METHODS: One hundred and thirty-one case-reports (81 women, 50 men) with 5FU-related toxicity were analyzed. RESULTS: The lower the DPD activity (10-504 pmol min(-1) mg(-1)), the higher the toxicity grade was scored (P < 0.01). Toxicity-related deaths occurred in nine patients (eight women) who significantly expressed lower DPD activity than other patients. Two of the deceased patients had normal DPD activity. The IVS14+1G>A mutation, analyzed in 93 patients, was detected in two patients (nonlethal toxicity). CONCLUSIONS: The IVS14+1G>A mutation may not help prevent toxicity and patients with normal DPD activity may develop life-threatening 5FUtoxicity.
Authors: M Raida; W Schwabe; P Häusler; A B Van Kuilenburg; A H Van Gennip; D Behnke; K Höffken Journal: Clin Cancer Res Date: 2001-09 Impact factor: 12.531
Authors: E Gamelin; M Boisdron-Celle; V Guérin-Meyer; R Delva; A Lortholary; F Genevieve; F Larra; N Ifrah; J Robert Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: E Lévy; P Piedbois; M Buyse; J P Pignon; P Rougier; L Ryan; R Hansen; B Zee; B Weinerman; J Pater; C Leichman; J Macdonald; J Benedetti; J Lokich; J Fryer; G Brufman; R Isacson; A Laplanche; E Quinaux; P Thirion Journal: J Clin Oncol Date: 1998-11 Impact factor: 44.544
Authors: S A Ridge; J Sludden; X Wei; A Sapone; O Brown; S Hardy; P Canney; P Fernandez-Salguero; F J Gonzalez; J Cassidy; H L McLeod Journal: Br J Cancer Date: 1998 Impact factor: 7.640
Authors: A B P van Kuilenburg; M-C Etienne-Grimaldi; A Mahamat; J Meijer; P Laurent-Puig; S Olschwang; M-P Gaub; R C M Hennekam; D Benchimol; S Houry; C Letoublon; F-N Gilly; D Pezet; T Andre; J-L Faucheron; A Abderrahim-Ferkoune; R Vijzelaar; B Pradere; G Milano Journal: Pharmacogenomics J Date: 2014-10-28 Impact factor: 3.550
Authors: Emma Borràs; Emma Dotor; Angels Arcusa; Maria J Gamundi; Imma Hernan; Miguel de Sousa Dias; Begoña Mañé; José A G Agúndez; Miguel Blanca; Miguel Carballo Journal: Front Genet Date: 2013-01-17 Impact factor: 4.599